Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCRU8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,598
Award facts
- Contract value 100% obligated
- $20,598.16 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $20,598.16 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for STELARA 90 mg/mL syringes. The contract, designated as delivery order 4570643446, was awarded on January 14, 2026, with an ultimate completion date of February 5, 2026, and includes no set-aside designation. DMS Pharmaceutical Group will perform the work at its Park Ridge facility and will serve as the sole contractor with no identified subcontractors on this award.
This delivery order is issued under DMS Pharmaceutical Group's umbrella Indefinite Delivery Contract with DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion acquisition vehicle designed to provide comprehensive pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide. The parent IDC, valued at $499,999,999 with a completion date of December 31, 2036, was awarded to DMS Pharmaceutical Group on November 13, 2025, and positions the company as a critical regional prime vendor contractor within DLA's global military medical supply chain. Through this vehicle, DMS Pharmaceutical Group supplies a diverse portfolio of branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals to support recurring medical needs across DoD healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FCRU8?
SPE2DR26FCRU8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 14, 2026.
How much is contract SPE2DR26FCRU8 worth?
The government has obligated $20,598 on SPE2DR26FCRU8.
Is contract SPE2DR26FCRU8 an order under another contract?
Yes. SPE2DR26FCRU8 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRU8 competed?
The extent of competition for SPE2DR26FCRU8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award